Patients with diabetes have a high cardiovascular risk, which can be efficiently addressed by the administration of glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1-RA). Nevertheless, the use of GLP-1-RA has so far been limited in cardiology. This review describes the existing evidence for cardiovascular benefits of GLP-1-RA and presents the available substances with recommendations on administration and titration and taking the side effects into consideration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00059-022-05130-w | DOI Listing |
Publication Analysis
Top Keywords
glp-1 receptor
8
receptor agonists
8
[heart diabetes
4
diabetes glp-1
4
agonists cardiology?]
4
cardiology?] patients
4
patients diabetes
4
diabetes a high
4
a high cardiovascular
4
cardiovascular risk
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!